SYK Stock Price, Performance & Company Data

Stryker’s stock fell after its Q2 report disappointed investors by missing estimates on results or guidance.

7 hours ago·Lightyear AI

13:30

15:10

16:45

18:25

20:00

About Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.

Ticker

$SYK

Sector

Health

Primary listing

NYSE

Employees

56,000

Headquarters

Portage, United States

Website

www.stryker.com

Stryker Metrics

BasicAdvanced

$133bn

40.28

$8.64

0.78

$2.60

1.01%

What the Analysts think about Stryker

Analyst ratings (Buy, Hold, Sell) for Stryker stock.

Bulls say / Bears say

The orthopedics segment saw 6.3% sales growth to $2.81 billion in Q1, topping the $2.51 billion analysts expected and highlighting resilience in its core implant franchise. (Reuters)

Q4 net sales climbed 11.4% to $7.20 billion, surpassing the $7.12 billion consensus, driven by 17.5% growth in MedSurg & Neurotechnology and 8.4% in Orthopaedics, underscoring diversified demand strength. (Reuters)

Stryker lifted its FY 2026 outlook, projecting 8.0–9.5% organic net sales growth and adjusted EPS of $14.90–$15.10, signaling management’s confidence in sustaining momentum and currency tailwinds. (Reuters)

Adjusted EPS of $2.60 and revenue of $6.02 billion in Q1 fell short of estimates of $2.98 and $6.35 billion, revealing near-term pressure on profitability and top-line momentum. (Reuters)

Softer demand for complex spinal and orthopedic procedures weighed on Q1 results, suggesting potential headwinds in key end-markets amid macroeconomic uncertainty. (Reuters)

A pro-Iran cyberattack in March disrupted Stryker’s electronic ordering and manufacturing, delaying surgeries and deferring approximately $375 million in sales, underscoring acute operational risks. (Bloomberg)

Data summarised monthly by Lightyear AI. Last updated on 31 Jul 2026.

Stryker Financial Performance

Revenues and expenses

Income statement
QuarterlyAnnual	Q3 24	QoQ growth
Revenue	$37bn	-39.75%
Net income	$45bn	107.52%
Profit margin	37.65%	6.78%

Stryker Earnings Performance

Company profitability

Earnings per share
QuarterlyAnnual	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24
Actual	$3.69	$2.85	$2.45	$2.42	-
Expected	$3.55	$2.61	$2.05	$2.31	$3.94
Surprise	3.94%	9.20%	19.51%	4.63%	-

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

The orthopedics segment saw 6.3% sales growth to $2.81 billion in Q1, topping the $2.51 billion analysts expected and highlighting resilience in its core implant franchise. (Reuters)

Adjusted EPS of $2.60 and revenue of $6.02 billion in Q1 fell short of estimates of $2.98 and $6.35 billion, revealing near-term pressure on profitability and top-line momentum. (Reuters)

Softer demand for complex spinal and orthopedic procedures weighed on Q1 results, suggesting potential headwinds in key end-markets amid macroeconomic uncertainty. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 31 Jul 2026.